TNR: Gout Journal Club https://t.co/vWNEof3F6b https://t.co/EgfqfKU1lx

QD Clinic: Cellulitis Paradoxes Dr. Richard Conway, Dublin, discusses a case of cellulitis and gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026. https://t.co/ZeYyISJrrE https://t.co/2Ih4QRa7FK

FDA Delays Gout Drug NASP with Complete Response Letter On June 26, 2026, SOBI received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) that will delay a decision on NASP, pending the company's answer to questions regarding the drugs https://t.co/NmPbWmYd0p

Non-gout drugs that may lower uric acid – losartan, amlodipine, ACE inhibitors, fenofibrate, atorvastatin, leflunomide, vitamin C, estrogen, and high-dose ASA. For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/vmNvqojAcS

Problems with treatment adherence in the management of gout Compared to common medical conditions such as hypertension, type 2 diabetes, hyperlipidemia or osteoporosis, where the reported drug adherence rates are between 50% to 70%, the drug adherence for gout is 37%. This https://t.co/OoLh0HUUH2

🎥 In this RheumNow Therapeutic Update, Dr. Nicola Dalbeth reviews the latest evidence on the Outcomes of Tophaceous Gout and what every rheumatologist should know. Watch now: https://t.co/KQmkdziLF5 #Gout #Rheumatology #MedEd #SystemicBurdenOfGout https://t.co/h8LhE5XW00

Netherlands pragmatic open-label RCT from 8 rheum centres tested T2T vs Sx Rx in 308 Gout pts starting ULT (87% male; 66 yrs). Remission (no flares & pain < 2) betw 18-24 mos was more in T2T pts (39% vs 24%; p=0.02), but more AE w/ Sx driven Rx (53 vs 42%) https://t.co/5g2dY5y900

Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud’s 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://t.co/S5Eg4AZSPU https://t.co/nG2p2g2Jc1

Challenges in Gout Diagnosis Dr. Angelo Gaffo in Birmingham, AL discusses the challenges in diagnosing gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026. https://t.co/LmTj7cvBGT https://t.co/VRVCrAo2TT

QD CLINIC: Senior Year Gout Daric Mueller, PA-C, discusses a case of difficult-to-treat gout in an individual first diagnosed at age 18 who is now in his early 30s. This QD Clinic is presented as part of RheumNow's "Gout: More than Flares" campaign. https://t.co/9GNk8ZqwyS https://t.co/hAFz6zPcay

Weight loss helps gout, but extreme weight loss (bariatric surgery, ketogenic diets) may trigger gouty attacks. (Not seen with GLP-1 agonist weight loss) For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/LGEENexSZ6

Subanalysis of SURMOUNT-1 Obesity trial l (2539 pts w/ BMI ≥ 30; tirzepatide vs PBO) showed 21% wt loss by wk 72 w/ TIRZ. Serum uric acid (SUA) decr by -0.69, -0.92, & -0.95 mg/dL on TIRZ (5, 10, & 15 mg qd). Wt loss explained 73% of SUA reduction. https://t.co/V0stEDC4lF https://t.co/t8qNNCrrGM